X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs STERLING BIOTECH - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE STERLING BIOTECH CADILA HEALTHCARE/
STERLING BIOTECH
 
P/E (TTM) x 18.5 -0.4 - View Chart
P/BV x 4.2 0.0 29,434.4% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 CADILA HEALTHCARE   STERLING BIOTECH
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
STERLING BIOTECH
Dec-13
CADILA HEALTHCARE/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs55811 5,314.3%   
Low Rs3623 10,632.4%   
Sales per share (Unadj.) Rs116.326.8 433.8%  
Earnings per share (Unadj.) Rs17.9-15.0 -119.5%  
Cash flow per share (Unadj.) Rs23.1-5.5 -423.4%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.454.9 155.6%  
Shares outstanding (eoy) m1,023.74267.87 382.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.00.3 1,524.9%   
Avg P/E ratio x25.7-0.5 -5,537.4%  
P/CF ratio (eoy) x19.9-1.3 -1,562.3%  
Price / Book Value ratio x5.40.1 4,250.3%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,6641,862 25,281.5%   
No. of employees `00011.81.4 872.9%   
Total wages/salary Rs m18,545547 3,391.6%   
Avg. sales/employee Rs Th10,072.75,303.3 189.9%   
Avg. wages/employee Rs Th1,569.1403.8 388.5%   
Avg. net profit/employee Rs Th1,547.7-2,959.0 -52.3%   
INCOME DATA
Net Sales Rs m119,0497,181 1,657.9%  
Other income Rs m1,13243 2,657.3%   
Total revenues Rs m120,1817,223 1,663.8%   
Gross profit Rs m28,475947 3,007.2%  
Depreciation Rs m5,3882,543 211.9%   
Interest Rs m9114,377 20.8%   
Profit before tax Rs m23,308-5,931 -393.0%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644-1,924 -293.3%   
Profit after tax Rs m18,292-4,007 -456.6%  
Gross profit margin %23.913.2 181.4%  
Effective tax rate %24.232.4 74.6%   
Net profit margin %15.4-55.8 -27.5%  
BALANCE SHEET DATA
Current assets Rs m82,00514,335 572.1%   
Current liabilities Rs m60,72049,809 121.9%   
Net working cap to sales %17.9-494.0 -3.6%  
Current ratio x1.40.3 469.3%  
Inventory Days Days73403 18.1%  
Debtors Days Days98171 57.6%  
Net fixed assets Rs m83,70355,432 151.0%   
Share capital Rs m1,024268 382.2%   
"Free" reserves Rs m86,42113,935 620.2%   
Net worth Rs m87,44514,701 594.8%   
Long term debt Rs m25,5519,478 269.6%   
Total assets Rs m180,65373,988 244.2%  
Interest coverage x26.6-0.4 -7,489.6%   
Debt to equity ratio x0.30.6 45.3%  
Sales to assets ratio x0.70.1 679.0%   
Return on assets %10.60.5 2,122.2%  
Return on equity %20.9-27.3 -76.8%  
Return on capital %22.0-6.4 -342.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m42,6831,860 2,295.0%   
Fx outflow Rs m11,24225 45,166.7%   
Net fx Rs m31,4411,835 1,713.5%   
CASH FLOW
From Operations Rs m9,1931,719 534.9%  
From Investments Rs m-9,737-3,148 309.3%  
From Financial Activity Rs m5151,426 36.1%  
Net Cashflow Rs m-29-3 852.9%  

Share Holding

Indian Promoters % 74.8 33.9 220.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.0 -  
FIIs % 5.9 9.9 59.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 11.0 39.3 28.0%  
Shareholders   44,069 21,482 205.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 21, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS